BIO0.HM Biotest GmbH & Co. KGaA

Healthcare Biotechnology Hamburg Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-15.3%
Dividend yield
0.12%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is BIO0.HM undervalued?

Graham number

The Graham number of Biotest GmbH & Co. KGaA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biotest GmbH & Co. KGaA fundamental analysis

No fundamental analysis for Biotest GmbH & Co. KGaA yet.

Biotest GmbH & Co. KGaA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biotest GmbH & Co. KGaA

Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest …

Full company profile